Clinical trials: EGFR Positive Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer (NSCLC)
Efficacy and Safety of 80mg Osimertinib in Patients With Non-small Cell Lung Cancer(NSCLC)
This will be a Phase II, open-label, single-arm, multicenter study of the efficacy and safety of osimertinib (80 mg orally once daily) in patients with LM associated with EGFRm+ NSCLC.
- Trial name
- BLOSSOM (NCT04563871)
- Testing
- 80mg Osimertinib
- Where
- 6 sites in South Korea
- Volunteers
- 73 people
- Sponsor
- Sehhoon Park
EGFR Mutation Positive Non Small Cell Lung Cancer
First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy
Phase I: evaluate the safety and tolerability two different dosing regimens of Thymosin alpha 1 in patients with advanced EGFR mutation positive NSCLC on Standard of Care (SoC) therapy.
- Trial name
- NCT02906163
- Testing
- Thymalfasin (Thymosin alpha 1, Ta1), SoC (tyrosine kinase inhibitor)
- Where
- 5 sites in Italy
- Volunteers
- 188 people
- Sponsor
- SciClone Pharmaceuticals
Lung Cancer
Early Access Program of Lazertinib in Republic of Korea
This early access program will be conducted to provide access to Lazertinib for adult patients with locally advanced or metastatic Non-small Cell Lung Cancer (NSCLC) with T790M mutation-positive after 1st/2nd generation EGFR TKIs…
- Trial name
- NCT04829422
- Testing
- Lazertinib 240 mg
- Sponsor
- Yuhan Corporation
Non Small Cell Lung Cancer
Randomized Gefitinib Trial
Patients with locally advanced (IIIB with effusion) or metastatic non-small cell lung cancer (NSCLC), EGFR FISH positive, candidate for a first-line platinum-based chemotherapy will be considered eligible for the trial.
- Trial name
- RANGE (NCT00807066)
- Testing
- Gefitinib, Platinum
- Where
- Italy
- Volunteers
- 1 people
- Sponsor
- Fondazione Humanitas per la Ricerca
Non-Small Cell Lung Cancer, EGFR Gene Mutation
D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC
To assess the efficacy and safety of D-0316 versus Icotinib, a standard of care epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in patients with locally advanced or Metastatic Non Small Cell Lung Cancer…
- Trial name
- NCT04206072
- Testing
- D-0316 Capsule, Icotinib Hydrochloride Tablets
- Where
- 2 sites in China
- Volunteers
- 362 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Carcinoma, Non-Small-Cell Lung, Lung Cancer
G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer
This was a study to investigate the potential clinical benefit of G1T38 as an oral therapy in combination with osimertinib in patients with EGFR mutation-positive metastatic non-small cell lung cancer.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Lung Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT03455829
- Testing
- G1T38, Osimertinib
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- G1 Therapeutics, Inc.
EGFR Positive Non-small Cell Lung Cancer, Adenocarcinoma
Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLC
This randomised, controlled, open-label, prospective trial is designed to assess the efficacy and safety of icotinib maintenance therapy after sequential Icotinib plus chemotherapy versus Icotinib maintenance therapy after…
- Trial name
- NCT02194556
- Testing
- Sequential and maintenance icotinib, Maintenance icotinib
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
EGFR Positive Non-small Cell Lung Cancer
A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients
There are unmet medical needs in patients who resist to EGFR TKIs, especially to osimertinib; APG-1252 shows synergy with osimertinib in both osimertinib treatment naïve and resistant cell lines.
- Trial name
- NCT04001777
- Testing
- APG-1252, Osimertinib Mesylate Tablets
- Where
- 4 sites in China
- Volunteers
- 80 people
- Sponsor
- Ascentage Pharma Group Inc.
EGFR Positive Non-Small Cell Lung Cancer,Adenocarcinoma
Icotinib Combined With Dihydroaremisinin (DHA) Therapy in Patients With Advanced NSCLC
The study was to evaluate the safety, PFS and ORR of icotinib/dihydroaremisinin (DHA)-based combination therapy in EGFR-mutated, advanced NSCLC patients who have gradually progressed disease after first-line icotinib treatment.
- Trial name
- NCT03402464
- Testing
- Icotinib combined dihydroaremisinin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking University Cancer Hospital & Institute
T790M Positive NSCLC Patients
Effect of Osimertinib in Ethnic Chinese With EGFR and T790M Mutated NSCLC
To assess the effectiveness and safety of osimertinib treatment in a real world setting.
- Trial name
- NCT03133234
- Testing
- osimertinib
- Where
- China
- Volunteers
- 47 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer, EGFR Mutation
A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer
Protocol Title A Study to Evaluate ANS014004 in Combination with EGFR-TKI in Patients with EGFR Mutation-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer The main purpose of this research study is to Find a safe…
- Conditions
- Non-Small Cell Lung Cancer, EGFR Mutation, Metastatic Lung Cancer, MET Alteration
- Trial name
- NCT07285148
- Testing
- ANS014004 + PLB1004, ANS014004 + Osimertinib
- Where
- United States
- Volunteers
- 253 people
- Sponsor
- Beijing Pearl Biotechnology Limited Liability Company
Non-Small Cell Lung Cancer
KOREA Study (Korea Osimertinib Real World Evidence Study to Assess Safety and Efficacy)
The objectives of this study are to assess the safety and efficacy of single agent Tagrisso (Osimertinib, hereinafter "the study drug") in a real world setting in adult patients with advanced or metastatic, epidermal growth…
- Trial name
- KOREA (NCT02777567)
- Where
- South Korea
- Volunteers
- 315 people
- Sponsor
- AstraZeneca
Immunotherapy, Chemotherapy
Clinical Study of Chemotherapy and Immunotherapy Combined With Lactobacillus Johnsonii in Patients With Multiple Irresectable Solid Tumors
This study plans to enroll 156 patients aged 18-75, who will be randomly divided into two groups to evaluate the clinical efficacy and safety of chemotherapy and immune therapy combined with Lactobacillus johnsonii in patients…
- Trial name
- NCT07191405
- Testing
- oral Lactobacillus johnsonii (1×10¹¹ CFU, twice daily)
- Volunteers
- 156 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
NSCLC
A Study of Toripalimab+ Pemetrexed Plus Carboplatin in Patients With EGFR-mutation Positive and T790M Negative After Progression on EGFR-TKI Treatment
JS001 combined with pemetrexed plus carboplatin for treatment of recurrent or advanced non-small-cell lung cancer with EGFR-mutation positive and T790M negative after progression on EGFR-TKI treatment：a multi-center, single arm…
- Trial name
- JS001 (NCT03513666)
- Testing
- Drug intervention
- Where
- 5 sites in China
- Volunteers
- 40 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Non Small Cell Lung Cancer
Neoadjuvant Lazertinib Therapy in EGFR-Mutation Positive Lung Adenocarcinoma Detected by BALF Liquid Biopsy
Complete surgical resection is the standard treatment in early-stage lung cancer. However, the patients with early resected Epidermal Growth Factor Receptor(EGFR)-mutated lung cancers have high recurrence rate.
- Trial name
- NCT05469022
- Testing
- Neoadjuvant lazertinib
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Konkuk University Medical Center
Colorectal Cancer, Non-small Cell Lung Cancer
Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib
This is a Phase 1 open-label, dose-escalation trial using "3+3" design, evaluating MM-151 co-administration with MM-121, MM-141, and trametinib at varying dose levels.
- Conditions
- Colorectal Cancer, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT02538627
- Testing
- MM-151, MM-121, MM-141
- Where
- 5 sites in United States
- Volunteers
- 5 people
- Sponsor
- Merrimack Pharmaceuticals
EGFR Tyrosine Kinase Inhibitors Plus VEGFR Inhibitors
A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations
The main purpose of this study is to evaluate the safety and efficacy of Apatinib in combination with Gefitinib as compared to placebo in combination with Gefitinib in participants with stage ⅢB-IV Non-squamous non-small-cell…
- Trial name
- NCT02824458
- Testing
- Apatinib, Gefitinib
- Where
- China
- Volunteers
- 246 people
- Sponsor
- Sun Yat-sen University
Lung Cancer Non-small Cell Stage IV
Combination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC Patients
The third generation epidermal growth factor receptor-tyrosine Kinase Inhibitor（EGFR-TKI） osimertinib has obvious curative effect for EGFR sensitive mutation and T790M mutation(PMID 27959700), but acquired drug resistance will…
- Trial name
- NCT04184921
- Testing
- Aspirin 100mg, Osimertinib 80 MG
- Where
- China
- Volunteers
- 216 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Non-small Cell Lung Cancer, Brain Metastases
the Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With Brain Metastases From EGFR Mutation-positive Non-small Cell Lung Cancer
Subject population：Patients with brain metastases from EGFR mutation-positive non-small cell lung cancer who have not received systemic treatment. Experimental design: Single-center, single-arm phase II clinical trial.
- Trial name
- NCT04978753
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Li-kun Chen
Non Small Cell Lung Cancer, T790M
Real-World Study of Aumolertinib in Patients With Advanced EGFR T790M-Positive NSCLC
The single-arm phase II APOLLO study demonstrated favorable antitumor activity and an acceptable safety profile for aumolertinib in patients with EGFR T790M-positive locally advanced or metastatic non-small cell lung cancer after…
- Conditions
- Non Small Cell Lung Cancer, T790M, EGFR Activating Mutation
- Trial name
- AUMO-RWE (NCT07838532)
- Testing
- Aumolertinib monotherapy （development code: HS-10296）
- Where
- China
- Volunteers
- 637 people
- Sponsor
- Xin Li